Next Phase of Growth at Gentris Corporation to be Led by New Executive Team Including New Hires Dr. Heath Knight and Mr. Joseph Kessler
February 20, 2014
Morrisville, N.C. – Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics solutions, biomarker testing and biorepository services, announced today the addition of Dr. Heath Knight as vice president, corporate development and Mr. Joseph Kessler, as chief operating officer. These two executives join the executive leadership team as the company anticipates its next phase of growth.
Creating “Holes” for a Lifetime- Refocusing the Culture at Gentris Corp and an Homage to It’s a Wonderful Life
Amelia Wall Warner, PharmD, RPh
CEO and President, Gentris Corporation
Date: November 5 – 6, 2013
Location: Cambridge, Massachusetts
Drug discovery is a long, costly process with a high attrition rate, and a personalized medicine strategy is needed to improve clinical outcomes. Identifying the subclass of patients who is likely to respond to drugs and developing biomarkers for patient stratification before recruitment for clinical trials would improve efficacy and response rates. Cambridge Healthtech Institute’s Inaugural Biomarkers for Patient Stratification meeting will explore the integration of biomarkers and companion diagnostics into drug development, case studies of using biomarkers to guide clinical decision making, molecular profiling approaches and their impact on clinical development, as well as personalized medicine initiatives at big pharma.
Date: November 4 – 5, 2013
Location: Indianapolis, Indiana
Today, biospecimen collections are used by multiple research groups for varying research aims, from basic research through clinical trials. A well-managed biobank is a critical prerequisite for high-quality biological research. The proper collection, processing, storage and tracking of biospecimens are critical components allowing researchers to better link molecular and clinical information. Thus, by necessity, biobanking is both a science and a business. Cambridge Healthtech Institute’s Fifth Annual Leaders in Biobanking: Maximizing Your Investment in Biospecimens addresses both the business and science of biobanking, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge research.
October 4, 2013
Morrisville, N.C. – Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that Gentris founder, Michael Murphy, and leading cancer pharmacogenomics expert, Dr. Howard McLeod, have joined the Board of Directors.
“I am excited to welcome Michael Murphy and Dr. Howard McLeod to the Board of Directors,” said Tim Gupton, Gentris Chairman. “They bring a tremendous wealth of scientific, industry, and regulatory experience to Gentris and will provide invaluable guidance on strategic opportunities as we drive a new phase of company growth. The Board looks forward to working with Gentris’ senior management to build upon our 12-year history of success in pharmacogenomics and biobanking and to develop cutting-edge solutions that enable clients to capitalize on the promise of personalized medicine.”
New Leadership Will Implement LabmatrixTM Software to Create Next Generation Biobanking Solutions
September 25, 2013
Morrisville, N.C. – Gentris® Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that it has partnered with BioFortis to integrate its LabmatrixTM and Qiagram™ software into Gentris’ laboratory operations. The LabmatrixTM and Qiagram™ software will provide an advanced platform for clients to view and manage samples housed in the Gentris biorepository, while simultaneously enhancing their ability to collect, harmonize, and integrate multiple data sources, e.g., clinical, molecular, patient, and biospecimen data. In addition, Gentris has recently hired John Doyle as Vice President of Information Technology to lead the implementation of BioFortis’ solution. John brings with him over 25 years of experience at IBM, which he will leverage as he continues to grow and enhance Gentris’ IT infrastructure.
September 16, 2013
Morrisville, N.C. – Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that it is expanding its genomic biomarker offering with the launch of Affymetrix GeneChip(R) Human Transcriptome Array (HTA) services. The GeneChip(R) HTA is a high resolution microarray for gene expression that is designed to empower next-generation expression profiling studies. The new array goes beyond gene-level expression profiling by providing the coverage and accuracy required to detect all known transcript isoforms produced by a gene.
Date: September 9 – 11, 2013
Location: Madrid, Spain
The NG30 Drug Discovery Europe brings together 30 senior decision makers and business leaders from across the region.
The event aims to solve your key business challenges. In particular, the ability to network and learn from industry peers through essential business conversation shaped by our three unique drivers of opportunity.
To learn more, please visit: http://www.ngthirtypharma.com/
Date: September 25 – 27, 2013
Location: Boston, MA
Speaker: Dr. Amelia Warner
This one-of-a-kind event is designed exclusively for executives working in biorepositories, biobanking, and sample management. Weaved throughout the program are workshops and sessions that focus attention on the growing need—and inherent challenges—of self-regulation and process standardization, domestically and abroad.
To learn more, please visit: http://www.iirusa.com/biorepositories/welcome-to-biorepositories.xml